The DOI matches its Crossref record; 74 of the 80 references it cites were found in a registry or an index.
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Open accessAbstract
This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and bloodHbA1clevels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia andHbA1c(by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1βand TNF-αlevels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“emerging data suggest that GLP-1-based therapies also showed anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues [17, 21–25].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sitagliptin (10 mg/kg/day) treatment decreased the expression of proinflammatory cytokine genes IL-1β and TNF-α in kidney of diabetic ZDF rat [25].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038 · cited 1×
“A normalization step preceded the gene expression quantification, using geNorm Housekeeping Gene Selection kit for Rattus norvegicus (Primer Design, Southampton, UK) and geNorm software (Ghent University Hospital, Center for Medical Genetics, Ghent, Belgium) to select optimal housekeeping genes for this study [42].”
MethodDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“In fact, incretin hormones are secreted from the gastrointestinal tract after food intake, in a nutrient-dependent manner, and stimulate glucose-dependent insulin secretion [22].”
BackgroundOxidative Stress as a Major Culprit in Kidney Disease in Diabetes
Forbes, J. M., Coughlan, M. T., & Cooper, M. E. (2008) · Diabetes · doi:10.2337/db08-0057 · Cited by 1,203
Suszták, K., Raff, A. C., Schiffer, M., & Böttinger, E. P. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0894 · Cited by 1,096
BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases.
Xiang, J., Chao, D., & Korsmeyer, S. (1996) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.93.25.14559 · Cited by 988 · cited 1×
“The authors report no conflict of interests.”
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“However, in T2DM patients the incretin effect is blunted; the “incretin defect,” is accompanied by reduced bioavailability of incretins, in part due to rapid inactivation by DPP-IV [23].”
BackgroundKim, D., Wang, L., Beconi, M. G., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K. A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 827 · cited 2×
“Our results showed that chronic treatment with sitagliptin is able to promote a partial, but significant, decrease of glycaemia and HbA 1c and also prevented the aggravation of weight loss, characteristic of a more advanced stage of T2DM, which confirms the results obtained in studies performed in humans [24–28].”
BackgroundResultRaz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614 · cited 2×
“Our results showed that chronic treatment with sitagliptin is able to promote a partial, but significant, decrease of glycaemia and HbA 1c and also prevented the aggravation of weight loss, characteristic of a more advanced stage of T2DM, which confirms the results obtained in studies performed in humans [24–28].”
BackgroundResult
Flagged first, then by citations
6 of the 80 references couldn’t be matched to a known paper.
Research works printed but not linked: 17
- 10.1038/ncpendmet0894 · DOI
- 2007, Kidney International, S49
- 2000, Journal of the American Society of Nephrology, 11, 1656, 10.1681/ASN.V1191656 · DOI
- 2000, Kidney International, 58, S3
- 10.2337/diabetes.55.1.225 · DOI
- 2003, American Journal of Physiology: Renal Physiology, 284, F455
- 10.2337/dc06-0703 · DOI
- 10.1152/ajprenal.00288.2005 · DOI
- 1999, Journal of Nephrology, 12, 159
- 10.1159/000025912 · DOI
- 1999, Current Medicinal Chemistry, 6, 311, 10.2174/0929867306666220208213543 · DOI
- 2013, Kidney International, 85, 579
- 2012, PLoS ONE, 7
- 2003, Kidney International, 64, S64
- 10.1046/j.1523-1755.2001.059002415.x · DOI
- 2011, Histology and Histopathology, 26, 1599
- 10.1210/en.2009-1166 · DOI
Cited by
Sorted by citations
Items 101–113 of 113
Sivasankari, V., & Manivannan, E. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00957 · Cited by 1
Abdel‐Emam, R. A., Abdel‐Zaher, A. O., Mohammad, G., & Abd-Allah, M. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2022.151549.1442 · Cited by 1
Safety of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: An Update
Mikhail, N., & Wali, S. (2021) · Journal of Infectious Diseases & Case Reports · doi:10.47363/jidscr/2020(2)132 · Cited by 1
“Interestingly, consistent with the anti-inflammatory action of DPP-4 inhibitors, patients who were receiving sitagliptin prior to admission had significant reduction in serum markers of inflammation such as CRP and procalcitonin as well as significant increase in lymphocytic count compared to the control group [12].”
The privileged position of glp-1 in diabetic nephropathy
Kunz-Martínez, W., & Pacheco, A. I. P. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00182
Akhbari, M. R., Saberi, S., Khaksari, M., Askaripour, M., & Jafari, E. (2026) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_101_25
Elgendy, A. A., Nematalla, H. A., Elharoun, M., & Abdel-Raheem, I. T. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104933
Ghofrani, F., Bibak, B., Sekeh, S. R. R., Mahmoud, B. B., Mohammadi, A., & Rameshrad, M. (2026) · North Khorasan University of Medical Sciences · doi:10.66224/nkums.18.1.43
Developmental origins of immunometabolic health
Alharithi, Y. J., Smith, G., & Maloyan, A. (2026) · Immunometabolism · doi:10.1097/in9.0000000000000075
Bobok, N., & Halushko, O. A. (2025) · Problems of ageing and longevity (Ukraine) · doi:10.71012/pro-ageing-2025-4-05 · Cited by 1
Therapeutic Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19
Mikhail, N., & Wali, S. (2020) · Journal of Virology Research & Reports · doi:10.47363/jvrr/2020(1)116
“Solerte et al [6] observed that patients who were receiving sitagliptin prior to admission had significant reduction in serum markers of inflammation such as C-reactive protein (CRP) and procalcitonin as well as significant increase in lymphocytic count compared to the control group.”
BackgroundDo DPP-4 Inhibitors Protect against COVID-19?
(2020) · SunKrist Endocrinology and Metabolism Research Journal · doi:10.46940/semrj.01.1003
Lipopolysaccharides et glucagon-like peptide 1 : des mécanismes moléculaires à la physiopathologie
Lebrun, L. (2016) · theses.fr (ABES) · doi:10.70675/2a6e27b7zd640z4026z814fzdc6a27d73fed
Kelany, M. A., Elotami, M., & Hakami, T. M. (2015) · Zagazig University Medical Journal · doi:10.21608/zumj.2015.4550
Metadata
- Authors
- Marques, C., Mega, C., Gonçalves, A., Rodrigues-Santos, P., Teixeira-Lemos, E., Teixeira, F., Fontes-Ribeiro, C., Reis, F., & Fernandes, R.
- Affiliations
- University of Coimbra (PT)
- Centro de Estudos em Educação Tecnologia e Saúde (PT)
- Institute of Immunology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
- Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
- Corresponding author
- Fernandes, Rosa
- ORCID
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-15
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4000968
- OpenAlex
- W2105771613
- Cited by
- 126
- References
- 80
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 15 · 2020: 15 · 2019: 10 · 2018: 11 · 2017: 21 · 2016: 15 · 2015: 8 · 2014: 1
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- Foundation for Science and Technology, Portugal (PEst-C/SAU/UI3282/2011, PEst-C/SAU/UI3282/2013, COMPETE)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- sitagliptin, type 2 diabetes, diabetic nephropathy, DPP-4 inhibitors, glucagon-like peptide-1, GLP-1 receptor, renal inflammation, apoptosis, Bax/Bcl-2 ratio, Bid, TNF-α, IL-1β, tubulointerstitial injury, glomerular lesions, glycemic control, Zucker diabetic fatty rats
- MeSH terms
- Sitagliptin Phosphate, Animals, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Inflammation, Kidney, Pyrazines, Rats, Zucker, Triazoles, Tumor Necrosis Factor-alpha, Apoptosis, Rats, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
